The U.S. Food and Drug Administration (FDA) has approved BRACAnalysis CDx® for use as a companion diagnostic to identify patients with HER2- metastatic breast cancer who are candidates BRACAnalysisCDx-Productfor treatment with AstraZeneca’s PARP inhibitor, Lynparza®(Olaparib).

BRACAnalysis CDx is the only FDA-approved test for use in this important indication.

The approval of BRACAnalysis CDx underscores the need for  patients with metastatic breast cancer to know their BRCA status and to help them receive the best available therapy.  As was shown in the OlympiAD study, the BRACAnalysis CDx test was proven to accurately identify those patients who benefited from treatment with Lynparza.

Myriad Genetics is actively working with all stakeholders to raise awareness of BRACAnalysis CDx, so that patients with HER2- metastatic breast cancer can be immediately tested to determine if they are likely to benefit from Lynparza.

You can get more information about BRACAnalysis CDx by visiting or by calling us at 1-800 469-7423.



Myriad Genetics at J.P. Morgan Healthcare Conference

Paul J. Diaz, president and chief executive officer, Bryan Riggsbee, chief financial officer, and Dale Muzzey, chief scientific officer, presented at the 41st annual J.P. Morgan (JPM) Healthcare Conference.